209 related articles for article (PubMed ID: 35948034)
1. Immunotherapy-Based Neoadjuvant Treatment of Advanced Microsatellite Instability-High Gastric Cancer: A Case Series.
Liu L; Woo Y; D'Apuzzo M; Melstrom L; Raoof M; Liang Y; Afkhami M; Hamilton SR; Chao J
J Natl Compr Canc Netw; 2022 Aug; 20(8):857-865. PubMed ID: 35948034
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of neoadjuvant immunotherapy in patients with microsatellite instability-high gastrointestinal malignancies: A case series.
Zhang Z; Cheng S; Gong J; Lu M; Zhou J; Zhang X; Li J; Shen L; Peng Z
Eur J Surg Oncol; 2020 Oct; 46(10 Pt B):e33-e39. PubMed ID: 32732092
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities.
Zhang X; Wu T; Cai X; Dong J; Xia C; Zhou Y; Ding R; Yang R; Tan J; Zhang L; Zhang Y; Wang Y; Dong C; Li Y
Front Immunol; 2022; 13():795972. PubMed ID: 35371084
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of microsatellite-instability in gastric and gastroesophageal junction cancer patients undergoing neoadjuvant chemotherapy.
Haag GM; Czink E; Ahadova A; Schmidt T; Sisic L; Blank S; Heger U; Apostolidis L; Berger AK; Springfeld C; Lasitschka F; Jäger D; von Knebel Doeberitz M; Kloor M
Int J Cancer; 2019 Apr; 144(7):1697-1703. PubMed ID: 30499151
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy in the neoadjuvant treatment of gastrointestinal tumors: is the time ripe?
Gervaso L; Ciardiello D; Oliveira RA; Borghesani M; Guidi L; Benini L; Algeri L; Spada F; Zampino MG; Cella CA; Fazio N
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38782539
[TBL] [Abstract][Full Text] [Related]
6. Complete Pathological Response After Neoadjuvant Short-Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI-H/dMMR Rectal Cancer.
Trojan J; Stintzing S; Haase O; Koch C; Ziegler P; Demes M; Jelas I
Oncologist; 2021 Dec; 26(12):e2110-e2114. PubMed ID: 34431576
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer.
Li S; Yu W; Xie F; Luo H; Liu Z; Lv W; Shi D; Yu D; Gao P; Chen C; Wei M; Zhou W; Wang J; Zhao Z; Dai X; Xu Q; Zhang X; Huang M; Huang K; Wang J; Li J; Sheng L; Liu L
Nat Commun; 2023 Jan; 14(1):8. PubMed ID: 36596787
[TBL] [Abstract][Full Text] [Related]
8. Clinical case of the neoadjuvant treatment with nivolumab in a patient with microsatellite unstable (MSI-H) locally advanced gastric cancer.
Chubenko V; Inusilaev G; Imyanitov E; Moiseyenko V
BMJ Case Rep; 2020 Sep; 13(9):. PubMed ID: 32963041
[TBL] [Abstract][Full Text] [Related]
9. [Localized MSI/dMMR gastric cancer patients, perioperative immunotherapy instead of chemotherapy: The GERCOR NEONIPIGA phase II study is opened to recruitment].
Cohen R; Pudlarz T; Garcia-Larnicol ML; Vernerey D; Dray X; Clavel L; Jary M; Piessen G; Zaanan A; Aparicio T; Louvet C; Tournigand C; Chibaudel B; Tougeron D; Guimbaud R; Benouna J; Adenis A; Sokol H; Borg C; Duval A; Svrcek M; André T
Bull Cancer; 2020 Apr; 107(4):438-446. PubMed ID: 32057467
[TBL] [Abstract][Full Text] [Related]
10. Low level of microsatellite instability correlates with short disease-free survival of gastric cancer patients undergoing neoadjuvant chemotherapy.
Jiang D; Shu C; Zhang W; Sun L; Zhang M; He Y; Owen G; Jin W; He D; Deng X; Liu X
Virchows Arch; 2021 Feb; 478(2):231-240. PubMed ID: 32588133
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint inhibitor therapy in locally advanced MSI GI malignancies.
Harrold EC; Keane F; Cercek A
Clin Adv Hematol Oncol; 2024 May; 22(4):162-173. PubMed ID: 38739719
[TBL] [Abstract][Full Text] [Related]
12. Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials.
Chao J; Fuchs CS; Shitara K; Tabernero J; Muro K; Van Cutsem E; Bang YJ; De Vita F; Landers G; Yen CJ; Chau I; Elme A; Lee J; Özgüroglu M; Catenacci D; Yoon HH; Chen E; Adelberg D; Shih CS; Shah S; Bhagia P; Wainberg ZA
JAMA Oncol; 2021 Jun; 7(6):895-902. PubMed ID: 33792646
[TBL] [Abstract][Full Text] [Related]
13. Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers.
Fucà G; Cohen R; Lonardi S; Shitara K; Elez ME; Fakih M; Chao J; Klempner SJ; Emmett M; Jayachandran P; Bergamo F; García MD; Mazzoli G; Provenzano L; Colle R; Svrcek M; Ambrosini M; Randon G; Shah AT; Salati M; Fenocchio E; Salvatore L; Chida K; Kawazoe A; Conca V; Curigliano G; Corti F; Cremolini C; Overman M; Andre T; Pietrantonio F
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35110358
[TBL] [Abstract][Full Text] [Related]
14. Prognostic implication of molecular subtypes and response to neoadjuvant chemotherapy in 760 gastric carcinomas: role of Epstein-Barr virus infection and high- and low-microsatellite instability.
Kohlruss M; Grosser B; Krenauer M; Slotta-Huspenina J; Jesinghaus M; Blank S; Novotny A; Reiche M; Schmidt T; Ismani L; Hapfelmeier A; Mathias D; Meyer P; Gaida MM; Bauer L; Ott K; Weichert W; Keller G
J Pathol Clin Res; 2019 Oct; 5(4):227-239. PubMed ID: 31206244
[TBL] [Abstract][Full Text] [Related]
15. Microsatellite instability and sex-specific differences of survival in gastric cancer after neoadjuvant chemotherapy without and with taxane: An observational study in real world patients.
Hiltner T; Kohlruss M; Herz AL; Lorenzen S; Novotny A; Hapfelmeier A; Jesinghaus M; Slotta-Huspenina J; Sisic L; Gaida MM; Weichert W; Ott K; Keller G
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7651-7662. PubMed ID: 37000259
[TBL] [Abstract][Full Text] [Related]
16. [Influence of neoadjuvant chemotherapy on microsatellite instability in gastric carcinoma].
Sun XW; Zhan YQ; Li W; Xu L; Li JT; Chen XJ; Zhang RH; Xu DZ
Ai Zheng; 2006 Dec; 25(12):1493-6. PubMed ID: 17166373
[TBL] [Abstract][Full Text] [Related]
17. Microsatellite instability in Gastric Cancer: Between lights and shadows.
Puliga E; Corso S; Pietrantonio F; Giordano S
Cancer Treat Rev; 2021 Apr; 95():102175. PubMed ID: 33721595
[TBL] [Abstract][Full Text] [Related]
18. Clinical Management of Gastric Cancer Treatment Regimens.
Boilève J; Touchefeu Y; Matysiak-Budnik T
Curr Top Microbiol Immunol; 2023; 444():279-304. PubMed ID: 38231223
[TBL] [Abstract][Full Text] [Related]
19. Unanticipated pathological clearance in two cases of clinical T4b dMMR/MSI-h advanced colorectal cancer: the potential of immune checkpoint inhibitors despite positive positron-emission tomography results.
Nakamura D; Yanagita T; Fujii Y; Watanabe K; Suzuki T; Ushigome H; Nishigaki R; Sugimura N; Tanaka M; Ogawa R; Takahashi H; Shimura T; Hotta Y; Matsuo Y; Kondo M; Furukawa-Hibi Y; Takiguchi S
Surg Case Rep; 2024 May; 10(1):105. PubMed ID: 38691233
[TBL] [Abstract][Full Text] [Related]
20. Response to neoadjuvant chemotherapy and survival in molecular subtypes of resectable gastric cancer: a post hoc analysis of the D1/D2 and CRITICS trials.
Biesma HD; Soeratram TTD; Sikorska K; Caspers IA; van Essen HF; Egthuijsen JMP; Mookhoek A; van Laarhoven HWM; van Berge Henegouwen MI; Nordsmark M; van der Peet DL; Warmerdam FARM; Geenen MM; Loosveld OJL; Portielje JEA; Los M; Heideman DAM; Meershoek-Klein Kranenbarg E; Hartgrink HH; van Sandick J; Verheij M; van de Velde CJH; Cats A; Ylstra B; van Grieken NCT
Gastric Cancer; 2022 May; 25(3):640-651. PubMed ID: 35129727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
